Display Settings:

Format

Send to:

Choose Destination
Curr Urol Rep. 2010 May;11(3):152-8. doi: 10.1007/s11934-010-0104-x.

Emerging therapies in castrate-resistant prostate cancer.

Author information

  • 1Division of Hematology & Oncology, Department of Medicine, Oregon Health & Science University, 3303 SW Bond Avenue CH14R, Portland, OR, 97239, USA.

Abstract

Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.

PMID:
20425621
[PubMed - indexed for MEDLINE]
PMCID:
PMC3682789
Free PMC Article

Images from this publication.See all images (1)Free text

Fig. 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk